1. Home
  2. RVSN vs BLRX Comparison

RVSN vs BLRX Comparison

Compare RVSN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

HOLD

Current Price

$4.45

Market Cap

10.9M

Sector

N/A

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$3.30

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSN
BLRX
Founded
2016
2003
Country
Israel
Israel
Employees
47
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
12.6M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
RVSN
BLRX
Price
$4.45
$3.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
18.1K
30.7K
Earning Date
03-31-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$860.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$2.15
52 Week High
$9.39
$5.05

Technical Indicators

Market Signals
Indicator
RVSN
BLRX
Relative Strength Index (RSI) 29.87 54.84
Support Level $4.20 $3.07
Resistance Level $5.21 $3.53
Average True Range (ATR) 0.33 0.22
MACD 0.07 -0.03
Stochastic Oscillator 14.28 54.10

Price Performance

Historical Comparison
RVSN
BLRX

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: